<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00365989</url>
  </required_header>
  <id_info>
    <org_study_id>UF018</org_study_id>
    <nct_id>NCT00365989</nct_id>
  </id_info>
  <brief_title>MR Guided Focused Ultrasound Treatment of Uterine Fibroids With Enhanced Sonication</brief_title>
  <official_title>A Clinical Study To Evaluate the Safety and Efficacy of MR Guided Focused Ultrasound Treatment of Uterine Fibroids With Enhanced Sonication Techniques</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InSightec</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InSightec</source>
  <brief_summary>
    <textblock>
      This is a phase 3 study to determine the safety of the new features to the FDA approved
      ExAblate device using a new method to ablate fibroids deemed Enhanced Sonication.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Uterine leiomyoma (fibroids) are the most common neoplasms of the female pelvis. These benign
      tumors are generally oval in shape, and often highly vascular. On T2 weighted MR imaging
      exams, or T1 exams with contrast, uterine fibroids are easily identifiable. They occur in
      20-25% of women of reproductive age and can cause a variety of problems generally described
      as either bleeding or mass effects from the fibroid. InSightec has developed an Enhanced
      Sonication (ES) technique for the ablation of these fibroids. This mode of tissue ablation
      has been added to the already FDA approved ExAblate system. The goal of this ES technique is
      to provide an additional treatment tool that will enhance the treatment effect without
      additional risks while preserving ALL clinical features of the current commercially approved
      version.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>Within 1 month of treatment</time_frame>
    <description>The study objective is to determine the safety of the new Enhanced Sonication technique and assure no new safety issues are introduced.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Mean Enhanced Sonication Normalized Thermal Dose Volume</measure>
    <time_frame>During treatment</time_frame>
    <description>The secondary end point of the study is to evaluate the mean normalized Enhanced Sonication thermal dose volume. Normalized dose volume is a function of the sonication dose volume divided by the energy transmitted measured from the the MR thermometry imaging.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>Within 1 month of treatment</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Uterine Leiomyoma</condition>
  <condition>Uterine Fibroids</condition>
  <arm_group>
    <arm_group_label>ExAblate Enhanced Sonication Test Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The intervention to be administered is ExAblate Enhanced Sonication. The purpose of this study is to examine the safety profile of the ExAblate Enhanced Sonication mode to insure that no new safety issues are introduced compared to the normal focused ultrasound mode.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ExAblate Enhanced Sonication</intervention_name>
    <arm_group_label>ExAblate Enhanced Sonication Test Arm</arm_group_label>
    <other_name>Magnetic Resonance guided Focused Ultrasound</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Women age 18 or older, who present with symptomatic fibroids

          2. Women who have given written informed consent

          3. Women who are able and willing to attend all study visits.

          4. Patient is pre or peri-menopausal (within 12 months of last menstrual period).

          5. Able to communicate sensations during the ExAblate procedure.

          6. Uterine fibroids, which are device accessible (i.e., positioned in the uterus such
             that they can be accessed without being shielded by bowel or bone).

          7. Fibroids(s) clearly visible on non-contrast MRI.

        Exclusion Criteria:

          1. Women who are pregnant, as confirmed by serum test at time of screening, or urine
             pregnancy test on the day of treatment

          2. Patient who desire to become pregnant in the future.

          3. Patients who are breast-feeding.

          4. Patients with an active pelvic inflammatory disease (PID)

          5. Active local or systemic infection

          6. Metallic implants that are incompatible with MRI

          7. Known intolerance to the MRI contrast agent (e.g. Gadolinium or Magnevist)

          8. Severe claustrophobia that would prevent completion of procedure in the MR unit.

          9. Extensive abdominal scarring in the beam pass or dermoid cyst of the ovary anywhere in
             the treatment path.

         10. Known or suspected pelvic carcinoma or pre-malignant conditions, including sarcoma and
             adenomatous hyperplasia.

         11. Pedunculated fibroids.

         12. Intrauterine device (IUD) anywhere in the treatment path

         13. Undiagnosed vaginal bleeding.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne Roberts, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Shaman, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>KNI</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Min, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cornell</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Gianfelice, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Toronto General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>George Holland, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lahey Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California at San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lahey Clinic</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KNI</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cornell Vascular</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>MG5 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.insightec.com</url>
    <description>Sponsor web page</description>
  </link>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>August 17, 2006</study_first_submitted>
  <study_first_submitted_qc>August 17, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2006</study_first_posted>
  <results_first_submitted>December 20, 2018</results_first_submitted>
  <results_first_submitted_qc>February 4, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">February 5, 2019</results_first_posted>
  <last_update_submitted>February 4, 2019</last_update_submitted>
  <last_update_submitted_qc>February 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fibroids</keyword>
  <keyword>leiomyoma</keyword>
  <keyword>neoplasm</keyword>
  <keyword>benign tumors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Out of the 83 subjects signing consent, 33 subjects failed additional study requirements and did not participate. Fifty (50) subjects were treated; 48 received enhanced sonications, 2 received only nominal sonications.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Enhanced Sonication Test Arm</title>
          <description>ExAblate 2000 Enhanced Sonication (ES) mode generates higher ultrasound energy absorption at the focal volume compared to normal sonications.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Out of the 50 treated subjects, 48 received Enhanced Sonications (ITT) and 2 received only normal sonications.</population>
      <group_list>
        <group group_id="B1">
          <title>Enhanced Sonication Test Arm</title>
          <description>ExAblate 2000 Enhanced Sonication (ES) mode generates higher ultrasound energy absorption at the focal volume compared to normal sonications.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="48"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>Only women with uterine fibroids qualified for this study.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Adverse Events</title>
        <description>The study objective is to determine the safety of the new Enhanced Sonication technique and assure no new safety issues are introduced.</description>
        <time_frame>Within 1 month of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Enhanced Sonication Test Arm</title>
            <description>ExAblate 2000 Enhanced Sonication (ES) mode generates higher ultrasound energy absorption at the focal volume compared to normal sonications.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Adverse Events</title>
          <description>The study objective is to determine the safety of the new Enhanced Sonication technique and assure no new safety issues are introduced.</description>
          <units>Adverse Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild/Moderate Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mean Enhanced Sonication Normalized Thermal Dose Volume</title>
        <description>The secondary end point of the study is to evaluate the mean normalized Enhanced Sonication thermal dose volume. Normalized dose volume is a function of the sonication dose volume divided by the energy transmitted measured from the the MR thermometry imaging.</description>
        <time_frame>During treatment</time_frame>
        <population>Of the 50 subjects treated, 39 were included in the thermal analysis per the protocol. Of the 11 subjects not eligible, 8 were not treated with at least 30% enhanced sonications. Three subjects received enhanced sonications at tissue depths greater that 70 mm from the skin line.</population>
        <group_list>
          <group group_id="O1">
            <title>Enhanced Sonication Test Arm</title>
            <description>ExAblate 2000 Enhanced Sonication (ES) mode generates higher ultrasound energy absorption at the focal volume compared to normal sonications.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Enhanced Sonication Normalized Thermal Dose Volume</title>
          <description>The secondary end point of the study is to evaluate the mean normalized Enhanced Sonication thermal dose volume. Normalized dose volume is a function of the sonication dose volume divided by the energy transmitted measured from the the MR thermometry imaging.</description>
          <population>Of the 50 subjects treated, 39 were included in the thermal analysis per the protocol. Of the 11 subjects not eligible, 8 were not treated with at least 30% enhanced sonications. Three subjects received enhanced sonications at tissue depths greater that 70 mm from the skin line.</population>
          <units>cc/KJ/sonication</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.67" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Adverse Events</title>
        <time_frame>Within 1 month of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ExAblate Enhanced Sonication Test Arm</title>
            <description>The intervention to be administered is ExAblate Enhanced Sonication. The purpose of this study is to examine the safety profile of the ExAblate Enhanced Sonication mode to insure that no new safety issues are introduced compared to the normal focused ultrasound mode.
ExAblate Enhanced Sonication</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Subjects with SAE reported</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Subjects with no AEs reported</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Subjects reporting AEs</title>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Subject deaths</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Enhanced Sonication Test Arm</title>
          <description>ExAblate 2000 Enhanced Sonication (ES) mode generates higher ultrasound energy absorption at the focal volume compared to normal sonications.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>All Pain/Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Dental</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Urinary frequency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal Vaginal Discharge</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Heavy menses</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Abdominal cramping</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin burn</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>IV bruise/numbness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Leg pain - sonication related</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Abdominal pain - sonication related</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Back pain - sonication related</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Skin pain - sonication related</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Pain - sonication related</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Nadir Alikacem</name_or_title>
      <organization>InSightec</organization>
      <phone>214-630-2000</phone>
      <email>nadira@insightec.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

